In vertebrates, the morphogenetic assembly of the primitive heart tube requires the medial migration and midline fusion of the bilateral myocardial epithelia [1, 2] . Several mutations that result in abnormal hearttube formation have been studied; however, an understanding of the underlying molecular and cellular mechanisms of the migration and fusion of these epithelial sheets is far from complete [1] [2] [3] [4] . In a forward genetic screen to identify genes regulating early zebrafish heart development, we identified a mutation in the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 1b (hmgcr1b) gene that affects myocardial migration to the midline and subsequent heart-tube morphogenesis. The mutant phenotype can be rescued with injections of mevalonate, the direct product of HMGCR activity. Furthermore, treatment of embryos with pharmacological inhibitors of isoprenoid synthesis, which occurs downstream of mevalonate production, resulted in defective heart-tube formation. Interestingly, in hmgcr1b mutant embryos and embryos treated with HMGCR inhibitors, both RasCT20-eGFP and RhoaCT32-eGFP fusion proteins were mislocalized away from the plasma membrane in embryonic myocardial cells. We conclude that protein prenylation, acting downstream of Hmgcr1b and possibly through Ras and, or, Rho signaling, is required for the morphogenesis of the myocardial sheets for formation of the primitive heart tube.
Results and Discussion
A Novel Mutant with Early Heart Morphogenesis Defects In order to more thoroughly understand the molecular, genetic, and cellular mechanisms of early heart formation, we carried out a forward genetic screen in zebrafish to identify additional genes regulating early heart development. The s617 mutation was originally identified as causing delayed myocardial migration to the midline. By 24 hr postfertilization (hpf), all s617 mutant embryos exhibit a thin, midline heart, a thick yolk extension, and pericardial edema (Figure 1 ). These defects become more pronounced by 36 and 48 hpf. Circulation is always absent in the mutant embryos.
In order to examine the heart phenotype more closely, we used a transgenic line, Tg(cmlc2:egfp) [5] , in which the cmlc2 promoter drives eGFP expression in the myocardial cells. We found that 21-somite-stage s617 mutant embryos show delayed migration of the bilateral myocardial cell populations to the midline compared to their wild-type siblings ( Figures 1F and 1G ). By 24 hpf, the wild-type hearts have jogged to the left ( Figure 1H ), whereas s617 mutant hearts remained at the midline ( Figure 1I ). The more severely affected mutant embryos also exhibited a delay in heart tilting and extension (Figure 1I) . By 48 hpf, when wild-type hearts have undergone looping morphogenesis, s617 mutant hearts were unlooped, thin midline structures.
Many mutations that cause myocardial migration defects have been shown to primarily affect endoderm development [6] [7] [8] [9] [10] [11] , suggesting that early heart morphogenesis requires an intact endoderm. In order to determine whether the s617 mutation was affecting endoderm development, we used a transgenic line in which the her5 promoter drives eGFP expression in the pharyngeal endoderm (Tg(0.7her5:egfp) ne2067 ) [12] . No obvious differences in pharyngeal endoderm development were observed between mutant embryos and their wild-type siblings before 24 hpf ( Figures 1J and 1K ). These data suggest that endoderm differentiation and early morphogenesis are unaffected in s617 mutant embryos.
The s617 Gene Encodes 3-Hydroxy-3-methylglutaryl coenzyme A reductase 1b To gain a better molecular understanding of the s617 phenotype, we isolated the s617 gene by positional cloning ( Figure 2 ). By using bulk-segregant analysis, we mapped the s617 locus to LG21. Fine mapping with 1301 diploid mutant embryos narrowed the s617 genomic region to a 1.6 cM span between CA repeat markers z6295 and z7405. Further fine mapping revealed that the s617 locus was located on the BAC CH211-149I8 (CR318660). One recombinant and zero recombinant markers were found in the 5 0 and 3 0 UTR regions of the hmgcr1b gene, respectively ( Figure 2A ). Because HMGCR had been implicated in regulating germ-cell migration in zebrafish and Drosophila [13, 14] , we focused on hmgcr1b as a candidate for the s617 locus. Sequencing hmgcr1b from s617 mutant embryos revealed a G to A (GGT/GAT) transition at position 1575 ( Figure 2B ). This mutation results in an amino acid change from glycine (Gly) to aspartic acid (Asp) at codon 497. Interestingly, this glycine residue lies at a highly conserved position in a region required for homodimerization or tetramerization of HMGCR (Figure 2C) [15, 16] . We confirmed that this mutation occurs at the genomic level in s617 mutant embryos by sequencing the relevant genomic region (data not shown).
To further test whether a defect in hmgcr1b is sufficient to cause a heart morphogenesis phenotype, we injected a morpholino antisense oligo designed against the hmgcr1b initiation ATG sequence into one-cellstage embryos. Morpholino injections resulted in a phenocopy of the s617 mutation, including pericardial edema, thick yolk extension, and heart morphogenesis defects. However, as expected based on the fact that hmgcr1b mRNA is present maternally [13] , more severe defects were common when the MO was injected at high doses (10 ng/embryo), with axis defects and frequent embryonic death by 24 hpf. Lower doses (5 ng/embryo) caused slightly less severe phenotypes that more closely resembled the s617 phenotype ( Figure 2D ).
In order to further establish whether the s617 mutant heart defects are due to a mutation in hmgcr1b, we treated embryos with statins, specific inhibitors of HMGCRs, and were able to phenocopy the s617 mutation ( Figures 2E and 2F ). Embryos were soaked in either 10 mM Atorvastatin or 1.2 mM Mevinolin starting at the end of gastrulation. Atorvastatin treatment resulted in embryos with slightly thicker yolk extensions and kinked notochord as previously described [13] , as well as midline, unlooped hearts ( Figure 2E ). The heart phenotype looked very similar to that seen in s617 mutant embryos. Soaking embryos in Mevinolin resulted in a much more severe heart and general somatic phenotype: Compressed and straight somites, a short tail, and a thick yolk extension were present as previously described [13] . Mevinolin treatments also blocked myocardial cell migration to the midline, resulting in cardia bifida ( Figure 2F ).
To further confirm that HMGCR activity is required for heart morphogenesis, we injected mevalonate, the direct downstream product of HMGCR, and were able to rescue the s617 mutant phenotype ( Figure 2G ). Injection of 2.3 nl of a 0.5 M mevalonate solution into one-cellstage embryos resulted in a rescue of the s617 mutant phenotype through the first 72 hpf. Embryos were analyzed at 48 hpf and then genotyped with a restriction fragment length polymorphism (RFLP) generated by the s617 mutation. Heart morphogenesis and function, as well as circulation, were restored in mutant embryos. However, a functioning Hmgcr1b is still required later in development because rescued mutant embryos developed edema by 5 dpf and did not survive to adulthood.
Protein Prenylation Is Required for Heart Morphogenesis Studies in zebrafish and Drosophila have shown that germ-cell migration requires protein prenylation, rather than cholesterol synthesis, downstream of HMGCR [13, 14] . To determine whether early heart morphogenesis also requires the prenylation branch (geranylgeranylation and farnesylation of proteins) downstream of mevalonate production, as well as to differentiate between the geranylgeranylation and farnesylation pathways, we treated embryos with pharmacological inhibitors of geranylgeranyl transferase 1 (GGT1) and farnesyl transferase (FT).
To test the requirement for GGT1 activity in myocardial epithelial migration, we injected one-to two-cell-stage embryos with 2 nl of a 1 mM solution of the GGT1 inhibitor GGTI-2177 in 25% DMSO. When observed at 48 hpf, treated embryos exhibited myocardial migration defects, including cardia bifida and partially fused midline hearts ( Figures 3E and 3F ). Other phenotypes exhibited by GTI-2177-treated embryos included pericardial edema and a thick yolk extension ( Figure 3C ). These phenotypes are similar, but much more severe, than those exhibited by s617 mutant embryos. Some of the treated embryos also exhibited other somatic defects, including cyclopia (20%, n > 50), short curved tails, and kinked notochords (85%). Control injections of 2 nl of 25% DMSO alone had no effect.
In contrast, treatment of embryos with the FT inhibitor L-744 resulted in much less severe phenotypes that more closely resembled those of s617 mutant embryos. An injection of 2 nl of a 1 mM solution of L-744 into onecell-stage embryos resulted in midline hearts similar to those observed in s617 mutant embryos ( Figures 3G  and 3H ). Pericardial edema and thick-yolk-extension phenotypes were also similar to those exhibited by s617 mutant embryos ( Figure 3D ). Treatment of embryos with up to 40 mM zaragozic acid, a specific inhibitor of squalene synthase in the sterol synthesis pathway downstream of HMGCR [17] , resulted in no observable heart defects (data not shown). The striking similarities of the phenotypes observed in s617 mutants, statintreated, and prenylation-pathway-inhibitor-treated embryos suggest that protein prenylation plays a central role in the migration of the myocardial epithelia to the midline. Furthermore, these data indicate that the heart migration defects in s617 mutant and statin-treated embryos are primarily caused by a lack of isoprenoid synthesis downstream of Hmgcr1b activity.
The posttranslational modification of proteins with an isoprenyl anchor plays an important role during localization of many proteins to the plasma membrane [18] [19] [20] . A CAAX motif (C, cysteine; A, aliphatic amino acid; X, any amino acid) at the carboxyl terminus of proteins is recognized by GGT1 or FT, which then adds the appropriate isoprenyl product to the cysteine residue in the CAAX motif. In order to test whether mislocalization of prenylation-mediated, membrane-targeted proteins occurred in the myocardial cells of embryos deficient in HMGCR activity, we treated transgenic embryos expressing RasCT20-eGFP (eGFP fused with the 20 amino acid carboxyl terminus of human Ras containing the CAAX motif) under the cmlc2 promoter (Tg(cmlc2:rasCT20-egfp) s883 ) with statins after the 12-somite stage. We observed the localization of RasCT20-eGFP by using confocal microscopy. In untreated embryos, RasCT20-eGFP was localized, as expected, to the plasma membrane of myocardial cells ( Figure 4A ). In contrast, treatment of embryos with Atorvastatin resulted in RasCT20-eGFP mislocalization to the nucleus and cytoplasm. Membrane localization, although not as robust as in untreated embryos, was still present ( Figure 4B ). Treatment of embryos with Mevinolin resulted in a striking mislocalization of RasCT20-eGFP to the nucleus and cytoplasm (Figure 4C) . Membrane localization was mostly absent, although some membrane localization was retained in a small number of cells.
Similarly, we tested whether a RhoaCT32-eGFP fusion protein was mislocalized in statin-treated embryos. Transient transgenic embryos expressing a fusion protein consisting of the 32 amino acid carboxyl terminus of zebrafish Rhoa attached to eGFP under the cmlc2 promoter (Tg(cmlc2:RhoaCT32-egfp)) were generated. Untreated embryos showed RhoaCT32-eGFP localized to the membrane of myocardial cells ( Figure 4D ). In both Atorvastatin-and Mevinolin-treated embryos, RhoaCT32-eGFP mislocalized to the cytoplasm ( Figures  4E and 4F) .
We further examined the localization of the RasCT20-eGFP fusion protein in s617 mutant embryos by generating s617;Tg(cmlc2:rasCT20-egfp) s883 fish. Compared to the membrane localization in wild-type sibling embryos ( Figure 4G ), s617 mutant embryos exhibited a mislocalization of RasCT20-eGFP to the cytoplasm and nucleus of myocardial cells ( Figure 4H ). These results indicate that Hmgcr1b activity is required for the targeting of this CAAX box-containing fusion protein to the membranes of the myocardial cells.
Although it is not known whether Rho or Ras mislocalization in myocardial cells contributes to the s617 heart phenotype, it appears likely that a combination of normally prenylated proteins are mislocalized, and their normal function perturbed, in statin-treated and s617 mutant embryos. These experiments further indicate that protein prenylation plays an important role in early zebrafish heart morphogenesis, likely through one or more isoprenoid-modified proteins, including Ras and RhoA.
Our data show that inhibition of GGT1 results in a much more severe myocardial migration defect than FT inhibition does. This stronger phenotype with GGT1 inhibition implies that one or more proteins, which are normally modified by geranylgeranylation, may be more critical for myocardial epithelium migration. Interestingly, Rho family members, including RhoA, are known to be a significant target for geranylgeranylation modification (G) Mutant embryos can be rescued by injection of mevalonate into one-cell-stage embryos. Individual embryos were imaged and then genotyped with a RFLP caused by the s617 mutation. Mevalonate-injected mutant embryos are indistinguishable from wild-type embryos through the first 72 hpf. [21] [22] [23] [24] [25] . Additionally, Rho family members are crucial regulators of cell migration [26] [27] [28] [29] [30] and appear to play a significant role in heart morphogenesis [31] .
HMGCR Activity Is Required Specifically during Myocardial Cell Migration
In order to determine when HMGCR activity is required for myocardial epithelial migration, we took advantage of our ability to inhibit HMGCR at specific times during development. All embryos were soaked in 10 mM Atorvastatin or 1.2 mM Mevinolin beginning at the following developmental stages: 256 cells, midgastrulation, tail bud, 9 somites, 15 somites, 20 somites, or 24 hpf, and the following data are summarized in Table S1 (in the Supplemental Data available with this article online). Embryos treated with Atorvastatin from the 256-cell stage exhibited mild axis defects and partially fused hearts by 1 dpf. Treatment of embryos starting from midgastrulation resulted in midline hearts, some reduction in heart size, and kinked notochords, as previously described [13] . Treatment of embryos after gastrulation resulted in wavy or kinked notochords in 28/35 embryos and delayed, midline hearts in 21/35 embryos (see Figure 2E) . Treatment of 9-somite-stage embryos resulted in 2/33 hearts showing delayed fusion, 18/33 midline hearts, and 13/33 wild-type hearts. In embryos treated after 15 somites, only 7/30 embryos had midline hearts, whereas most embryos exhibited wild-type hearts. Atorvastatin treatments after myocardial migration had taken place (20 somites) caused no observable heart defects. Atorvastatin treatments, therefore, reveal a requirement for HMGCR activity before and during precardiac mesoderm migration (15-20 somites) for heart morphogenesis.
We also tested the timing for the requirement of HMGCR activity for heart morphogenesis with Mevinolin, another statin that causes stronger somatic phenotypes than Atorvastatin. Mevinolin treatment of 256-cell-stage embryos resulted in severe axis defects (14/14), necrosis, and embryo death by 1 dpf. Mevinolin treatment beginning during gastrulation resulted in 20/20 embryos with short axis, straight somites, yolk-extension thickening, and bifid, reduced hearts. Treatment of embryos after gastrulation resulted in 35/35 embryos with short axis, straight somites, thick yolk extension; 30/35 embryos had bifid, reduced hearts (see Figure 2F ) and 5/ 35 embryos had reduced, midline hearts at 1dpf. By 48 hpf, all of these embryos were dead. Cardia bifida, a thick yolk extension, a short tail, and straight somites (36/47) were also observed in embryos treated after 9 somites, but with an increased survival rate (7/47 dead by 48 hpf). Interestingly, treatment of embryos starting at 15 somites resulted in 25/25 embryos with cardia bifida or partially fused hearts, as well as short tails, a thick yolk extension, and pericardial edema. Even embryos treated as late as 20 somites showed heart migration defects, including partial fusion and midline hearts. Treatments after 24 hpf resulted in midline, unlooped hearts and a slightly thickened yolk extension. These experiments reveal a requirement for HMGCR activity for heart morphogenesis during the stages that the myocardial epithelia are migrating and fusing at the midline (15-20 somites) . Subsequent heart morphogenesis (tilting, left-jogging, and looping) also appears to require HMGCR activity, as revealed by post-19 and 24 hpf Mevinolin treatments. Although early statin treatment (before 15 somites) reveals a requirement for HMGCR activity for both general embryonic and heart development, only heart development is significantly affected in embryos treated after 15 somites. This decoupling of the statin-induced heart defects from general somatic defects reveals a specific requirement for HMGCR activity during early vertebrate heart morphogenesis.
In studies in Drosophila, it was recently reported that HMGCR activity is required for heart formation [32] . Yi et al. showed a cell-autonomous requirement for HMGCR activity, via geranylgeranylation of the G protein Gg1, in the cardioblasts for their adhesion to pericardial cells [32] . Our data show a similar requirement for HMGCR activity for heart morphogenesis in vertebrate embryos. HMGCR appears to be required in zebrafish at an earlier step of heart formation, i.e., during the migration of the myocardial cells to the midline and subsequent assembly of the heart tube at the midline. However, it appears that the insertional allele used in the Drosophila study is not a null and that a more severe EMS allele leads to a heart phenotype that could be interpreted as a delayed migration or fusion defect ( [32] , Figure 2B ). Alternatively, it is possible that maternally provided HMGCR activity can sustain heart development to a later stage in Drosophila than it does in zebrafish.
Conclusion
Our study shows a requirement for HMGCR activity for the medial migration and fusion of the vertebrate myocardial epithelium, as well as the subsequent tilting and looping morphogenesis of the heart. HMGCR appears to function largely through isoprenoid synthesis and the posttranslational prenylation of proteins in regulating early heart morphogenesis. We found that GGT1 inhibition resulted in severe myocardial migration defects. Furthermore, statin treatments were found to cause the striking mislocalization of a Rhoa-GFP fusion protein in myocardial cells, suggesting that this important regulator of the cytoskeleton and cell migration requires robust HMGCR activity in the myocardial epithelium. These results, together with those recently reported in Drosophila [32] , reveal another element in the regulation of early heart morphogenesis and give us further insight into the possible molecular causes of congenital heart disease. ; Tg(cmlc2:rasCT20-egfp) embryos exhibit mislocalization of RasCT20-eGFP in the cytoplasm and nucleus (H).
Experimental Procedures
Zebrafish Strains and Care Adult and embryonic zebrafish were raised and cared for in accordance with standard laboratory procedures [33] . We used the following zebrafish mutant and transgenic strains: hmgcr1b s617 , Tg(cmlc2:egfp) [5] , Tg(0.7her5:egfp) ne2067 [12] , and Tg(cmlc2: rasCT20-egfp) s883 . A mutagenesis screen was carried out in collaboration with Herwig Baier's lab as previously described [34, 35] .
Fluorescence and Confocal Microscopy and Analysis Tg(cmlc2:egfp) and Tg(0.7her5:egfp) ne2067 embryos were imaged live with a Zeiss SteREO Lumar V12 microscope or Zeiss Stemi SV11 dissecting microscope and a Zeiss AxioCam. Brightfield images were aquired with a Zeiss Stemi SV11. Other embryos were fixed overnight at 4 C in 4% paraformaldehyde in PBS. Vibratome sections of embryos were performed with a Leica VT1000S and mounted on slides in Vectashield (Vector Laboratories) for imaging on a Zeiss LSM5 Pascal confocal microscope.
Cloning of the hmgcr1b Locus Zebrafish CA repeat microsatellite primers were obtained from the Massachusetts General Hospital Zebrafish server website (http:// zebrafish.mgh.harvard.edu). Fine mapping with 1301 diploid mutant embryos narrowed the region of interested to a single bacterial artificial chromosome (BAC) CHORI-211 149I8 (CR318660) with a one recombinant marker and a two recombinant marker flanking a 44 kb region. This BAC was sequenced and assembled by the Sanger Center Danio rerio Sequencing Project. This region contains two putative open reading frames (ORFs), hmgcr1b (AI497311) and GPBP (BC088384), based on GENESCAN gene prediction software [36] . An ATG morpholino to GPBP (Gene-Tools) was injected into onecell-stage embryos and caused no obvious phenotype (data not shown). Subsequently, one and zero recombinant markers were found in the 5 0 region and 3 0 region of the hmgcr1b gene, respectively. The hmgcr1b gene was sequenced from cDNA, and the genetic lesion in hmgcr1b was confirmed by sequencing of genomic DNA. A restriction fragment length polymorphism (RFLP) introduced by the s617 mutation was resolved with forward (5 0 -TGTGTGAGG ATGTGGAGCTT-3 0 ) and reverse (5 0 -GACTCACTGTGACGGCTCTG-3 0 ) primers and digested with FokI. (Injection of hmgcr1b mRNA into wild-type and s617 mutant embryos caused deleterious effects, a result that precluded rescue experiments by this method.) The hmgcr1b ATG morpholino (5 0 -TCATCATCATCACGGTCTTCAGTGG-3 0 ) was designed by Gene-Tools, Inc.
Transient Transgenic Embryo Production
The pCS2+ cmlc2:rasCT20-eGFP construct (gift of Le Trinh) was modified by replacement of the C-term of hras with the C-term of zebrafish rhoa (rhoaCT32). rhoaCT32 was amplified with the forward+XbaI (5 0 -AGATCTAAAACTAAGGAGGGCGTGAG-3 0 ) and reverse+BglII (5 0 -TCTAGACCTCCCTCGTTCTTCTCATT-3 0 ) primers on a 2 dpf cDNA library. The pCS2+ cmlc2rhoaCT32-egfp construct was linearized with SnaB and injected into recently fertilized embryos so that transient transgenic embryos expressing RhoaCT32-eGFP in myocardial cells could be generated.
Pharmacological Treatment of Embryos
Embryos were soaked in 1.2 mM Mevinolin (Sigma), 10 mM Atorvastatin (Pfizer), or 40 mM Zaragozic acid (Sigma) in embryo water (beginning at the developmental stages indicated). One-cell-stage embryos were injected with 2.3 nl of a 0.5M mevalonate solution or 2 nl of the FT inhibitor L-744 (CalBiochem) or GGTI inhibitor GGTI-2177 (CalBiochem) at a 1 mM concentration in 25% DMSO.
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